Tessera Defense and Homeland Security Inc
HLSQHealthcare|Biotechnology|US
$0.13
+0.01 (+6.85%)
About
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
Stock Price
-90.3%(1Y)
1M
-54.5%
3M
-90.3%
6M
-90.3%
YTD
-90.3%
1Y
-90.3%
3Y
-90.3%
5Y
-90.3%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$362.0K
Employees20
CEOMichael Oster
IPO DateSep 11, 2026
Beta1.38
52-Week Range$0.11575 – $85
Avg Volume1,305,297
ExchangeAMEX
Websitethlsq.ai
Ownership
Shares Outstanding2.7M
Recent News
Zorronet Secures Additional Order from Major Israeli Defense Organization to Extend Range of Autonomous Systems
Oct 29, 2026 · prnewswire.com
Tessera Defense and Homeland Security Inc. (HLSQ) Shareholder/Analyst Call Prepared Remarks Transcript
Oct 20, 2026 · seekingalpha.com
Zorronet Secures Initial Commercial Order for Its Edge AI Systems from a Leading Global Defense Company
Oct 20, 2026 · prnewswire.com
Tessera Integrates Autonomous OSINT Capabilities Designed to Anticipate Threats and Act on External Intelligence
Oct 19, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 04:13 AM